ARTICLE | Clinical News
CS055: Phase I started
October 4, 2010 7:00 AM UTC
Huya began a U.S. Phase I trial to evaluate oral HBI-8000. Huya has exclusive rights from Shenzhen Chipscreen to the compound outside of China, where the companies are co-developing the compound (see ...